Literature DB >> 1594018

Prognostic factors and treatment decisions in axillary-node-negative breast cancer.

W L McGuire1, G M Clark.   

Abstract

Entities:  

Mesh:

Year:  1992        PMID: 1594018     DOI: 10.1056/NEJM199206253262607

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  54 in total

Review 1.  Adjuvant therapy for breast cancer: who should get what?

Authors:  H K Chew
Journal:  West J Med       Date:  2001-04

Review 2.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

Review 3.  Prognostic factors in breast cancer: current and new predictors of metastasis.

Authors:  D F Hayes; C Isaacs; V Stearns
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

4.  Three dimensional staging of breast cancer.

Authors:  I L Wapnir; D E Wartenberg; R S Greco
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

6.  Plasma gelatinase levels in patients with primary breast cancer in relation to axillary lymph node status, Her2/neu expression and other clinicopathological variables.

Authors:  J Decock; W Hendrickx; H Wildiers; M R Christiaens; P Neven; M Drijkoningen; R Paridaens
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 7.  Diagnosis and management of spinal metastases from breast cancer.

Authors:  F E Landreneau; R J Landreneau; R J Keenan; P F Ferson
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 8.  Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.

Authors:  Deepika Neelakantan; David J Drasin; Heide L Ford
Journal:  Cell Adh Migr       Date:  2014-10-16       Impact factor: 3.405

9.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

Review 10.  Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients.

Authors:  W C Wood
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.